Johnson & Johnson

JNJ

BUY
Jul 28, 2026Neutral

Decision brief

The at 18.21 and 10-year yield at 4.60% reflect a neutral-to-cautious market regime, but JNJ's low beta and income profile provide relative resilience. The stock recently touched a new 52-week high of $274.89 before closing at $266.73, indicating potential resistance near that level. Fundamentally, Q2 2026 adjusted of $2.90 beat estimates by 1.6%, and full-year guidance was raised for the second time. FY2026 consensus has risen to $11.68 over the past 30 days, and FY2027 to $12.83. The forward of 20.8x is slightly below the 5-year average, offering reasonable entry for a high-quality compounder. A DCF analysis suggests the stock may be 31% undervalued with an intrinsic value near $388. The FDA De Novo authorization for Ottava on July 22 provides a major new MedTech catalyst, and multiple analyst price target raises support the thesis. Insider selling by senior executives remains a caution, but the director's purchase in July provides a slight offset. Technically, the stock is in a strong uptrend above the 50-day ($247) and 200-day ($221), with histogram turning positive and at 65, indicating improving momentum. is rising, confirming accumulation. However, the recent intraday reversal from the high suggests potential short-term consolidation or pullback. The next earnings date is October 13 (76 days away), so event risk is low. Overall, the setup is constructive with a bullish fundamental and technical posture, but the near-term risk-reward is less compelling at current levels, warranting a HOLD for the 1-month horizon while maintaining BUY for longer-term horizons.

Decision

Live price

$266.73

Recommendation score

76%
76%

Confidence

75%
75%

Outlook by horizon

1M

HOLD

Near

6M

BUY

Mid

1Y

BUY

Long

Primary catalyst

FDA authorization of Ottava robotic surgery system on July 22, which positions JNJ in the fast-growing surgical robotics market and could drive meaningful revenue from 2027.

Stability ClassDefensive CompounderPortfolio RoleCore AnchorDrawdown RiskLowRisk ProfileConservativeDividend KingOttava ApprovalUpward RevisionsNew 52-Week HighTalc OverhangInsider SellingMedTech RoboticsPipeline Momentum
Decision Workspace

Price Map

60-day setup

Price rail

$266.73
Stop
Now
$241
$257
$273
$289
Stop loss

$245.00

Entry

$255.00 - $262.00

Exit

$275.00 - $285.00

Risk / reward

1.5x

Watch size

Downside to stop

-8.1%

Upside to exit

+6.8%

Position sizing

Given the near 18 and positive catalyst momentum, a normal-sized position is appropriate for long-term investors. Traders may consider waiting for a pullback to the 20-day ($257) or 50-day ($247) for a better entry, as the stock is near its 52-week high and may consolidate.

Thesis Snapshot

Why It Works

JNJ offers a rare combination of defensive stability, strong pipeline momentum, and a 64-year dividend growth streak. The Q2 beat and raised guidance demonstrate operational resilience. The Ottava robotic surgery approval opens a new high-growth MedTech avenue. With a forward of 20.8x and AAA credit rating, the stock is reasonably valued, and a DCF analysis suggests 31% upside to intrinsic value near $388. Upward estimate revisions and analyst upgrades confirm improving sentiment.

What Breaks It

Talc litigation overhang remains unresolved, with potential for larger verdicts or a multi-billion settlement. Stelara biosimilar erosion could pressure earnings for years, as seen in the 55% Q2 sales decline. The high (4.40) suggests limited near-term growth relative to valuation. Insider selling by CEO and CFO raises caution. The stock's 8% rally in just nine days may leave it vulnerable to a near-term pullback, especially after hitting a new 52-week high and reversing intraday on high volume.

A sustained break and close below the 50-day ($247.01) and the $245 support level would invalidate the near-term bullish setup and suggest a deeper correction toward the 200-day ($221.49).

  • Talc litigation costs exceeding current reserves, e.g., a large jury award or forced settlement exceeding $1B.
  • Stelara biosimilar erosion accelerating faster than expected, causing further revenue declines in immunology.
  • Broader market risk-off shift or rising yields compressing defensive multiples further.
  • MedTech weakness, particularly in Cardiovascular devices, if competitive pressures or procedure volume uncertainty persist.
  • Insider selling by senior executives may indicate near-term headwinds.

Watch Next

  • Next earnings: Oct 13, 2026
  • FDA authorization of Ottava robotic surgery system on July 22, which positions JNJ in the fast-growing surgical robotics market and could drive meaningful revenue from 2027.
Signal Dashboard

Decision inputs

6 signals

Fundamental

1.5%

Upside to analyst mean target

JNJ trades at a forward of 20.8x, slightly below its 5-year average of ~21x and near the sector median. The ratio of 4.40 reflects near-term earnings pressure from Stelara biosimilar erosion, but long-term pipeline visibility supports a fair valuation. of 19.2x is in line with large-cap pharma peers. The mean analyst target of $270.59 implies a modest 1.4% upside from $266.73, but the wide range ($190-$305) highlights talc litigation uncertainty. A recent DCF analysis suggests the stock could be 31% undervalued, with an intrinsic value of ~$388. After the Ottava approval, MedTech growth narrative improves, potentially supporting multiple expansion. For a high-quality defensive compounder, current multiples offer reasonable value for long-term investors.

Technical

Bullish

Trend quality

Price ($266.73) remains well above the 200-day ($221.49) and 50-day ($247.01). The golden cross ( > ) has been intact since June. The stock recently traded to a new 52-week high of $274.89 intraday on 7/28 before closing at $266.73, indicating resistance at the high and potential for a pullback. The longer-term trend is bullish, with the 50-day providing dynamic support. The bounce from the July 15 low of $245.49 was strong, and the stock has reclaimed the 20-day ($257.45). Overall trend structure remains bullish but extended.

Earnings

76d

Steady

Q2 2026 adjusted of $2.90 beat estimates of $2.85 by 1.6%; revenue of $25.31B beat consensus of $25.18B; full-year guidance was raised for the second time, and the stock has since recovered on positive analyst reactions and the Ottava approval.

News

Mixed-Bullish

Headline tone

FDA authorization of Ottava robotic surgery system on July 22, which positions JNJ in the fast-growing surgical robotics market and could drive meaningful revenue from 2027.

Macro

Neutral

4.60% 10Y / 18.2 VIX

at 18.21 indicates a neutral-to-cautious environment; rising 10-year yields at 4.60% modestly compress defensive multiples, but JNJ's low beta (0.24) and 2.02% dividend yield provide relative resilience.

Stability

Defensive Compounder

Core Anchor

Johnson & Johnson remains a quintessential defensive compounder with an AAA credit rating, 64-year dividend growth streak, low beta of 0.24, and diversified healthcare revenue. The strong free cash flow generation ($16.9B) and institutional ownership (76.8%) provide stability. The recent FDA approval of Ottava robotic surgery opens a new MedTech growth avenue, while the pharmaceutical pipeline including DARZALEX and CARVYKTI sustains above-market growth. Drawdown risk is limited by structural support near the 50-day ($247) and a resilient balance sheet, though talc litigation and Stelara erosion require monitoring. This stock is suitable as a Core Anchor for conservative long-term investors seeking reliable income and capital preservation.

Analyst Spread

Mean Target

$270.59

High / Low

$190 / $305

Median Target

$274.00

Consensus range

$190 - $305

— analysts
Mean
$190$271$305

Consensus

Consensus shows 5 Strong Buy, 11 Buy, 6 Hold, 1 Sell (total 23 analysts). The mean target of $270.59 implies 1.4% upside, with a spread from $190 to $305, reflecting talc litigation uncertainty. The number of Buy-rated analysts and recent upward revisions indicate improving sentiment. The Ottava catalyst and raised guidance have solidified buy-side conviction.

Positioning Pulse

Insider Signal

Moderate Sell

Net Bias

Sell-heavy

Insider Own.

0.0%

Institutional Own.

76.8%

Interpretation

Recent insider selling by senior executives outweighs buying, suggesting near-term caution, though the CEO and CFO sales are often pre-planned. The small director purchase is a positive but insufficient signal to offset the selling.

Notable activity

CEO Joaquin Duato sold $12.6M in shares (likely pre-planned). CFO Joseph Wolk exercised and sold 68,890 shares (tax-related). COO Kathryn Wengel sold $3.28M. Director Mark Weinberger purchased $147k in open market.

Market Context

Industry

Drug Manufacturers - General

Mixed-Bullish

Sentiment

23

Tracked names

5

Grouping

industry

Drug Manufacturers - General industry is currently Mixed-Bullish with an average recommendation score near 64. positioning is broadly steady, and leadership is concentrated in LLY, ABBV, NVO.

Rotation Drivers

  • Recommendation changes across Drug Manufacturers - General industry are relatively flat, which suggests the group is still searching for a clean direction.
  • 4 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bullish.
  • Leadership is concentrated in LLY, ABBV, NVO, so those names are the cleanest read on group-level capital rotation.

Leaders To Watch

Related leaders

  • LLY

    Eli Lilly and Company

    Leader

    Score

    56

    Price

    $1220.66

    Market Cap

    $1.09T

  • ABBV

    AbbVie Inc.

    Leader

    Score

    72

    Price

    $263.20

    Market Cap

    $465.02B

  • NVO

    Novo Nordisk A/S

    High Momentum

    Score

    50

    Price

    $50.96

    Market Cap

    $225.34B

  • AMGN

    Amgen Inc.

    Key Peer

    Score

    65

    Price

    $393.10

    Market Cap

    $212.16B

Themes

Next-Gen Oncology and Immunotherapy

Score: 65

Bullish

JNJ's oncology portfolio is a key growth driver, with DARZALEX, CARVYKTI, and TECVAYLI gaining share. The company is a leader in CAR-T and bispecific antibodies. Q2 results highlighted strong performance of Tremfya (+72.5%) and successful launches of ICOTYDE and INLEXZO. The pipeline continues to offset Stelara erosion. Recent analyst commentary underscores strong commercial execution.

The Q2 earnings call underscored strong commercial execution in oncology and immunology, with Tremfya and new drug launches driving above-consensus pharma sales.

  • Increasing adoption of CAR-T and bispecific therapies in earlier treatment lines
  • Expanding labels for DARZALEX and CARVYKTI driving sustained revenue growth

MedTech Robotics

Score: 60

Mixed-Bullish

JNJ's entry into robotic surgery with the Ottava system positions it to compete in a growing market dominated by Intuitive Surgical. The FDA authorization covers soft-tissue procedures. Adoption may be gradual, and the competitive landscape is intense, but JNJ's commercial scale and hospital relationships provide an edge. Q2 MedTech growth slowed to 4.5%, but Vision, Orthopedics, Surgery accelerated. The Ottava approval is a key catalyst for the segment.

The FDA De Novo authorization of Ottava on July 22 provides a new growth catalyst in surgical robotics.

  • Rising preference for minimally invasive surgeries and robotic assistance
  • JNJ's strong track record in commercializing MedTech products and extensive hospital network
Key Stats
23 metrics total

Market Cap

$642.79B

P/E (TTM)

30.9

Forward P/E

20.8

Revenue Growth

6.6%

ROE

25.7%

Beta

0.23

Full Metric Set

17 additional stats

Valuation Stack

Multiples and cash-flow framing.

Price / Sales

6.6

Price / Book

7.6

EV / EBITDA

19.2

Quality & Balance Sheet

Margins, leverage, and liquidity.

Gross Margin

68.1%

Operating Margin

29.2%

Debt / Equity

57.7

Current Ratio

1.09x

Quick Ratio

0.73x

Positioning & Range

Short interest and 52-week location.

Short % Float

1.3%

Short Ratio

3.04x

52W High

$274.89

52W Low

$164.23

From 52W High

-3.0%

From 52W Low

62.4%

Company Classification

Sector and industry context.

Sector

Healthcare

Industry

Drug Manufacturers - General

Additional Signals

Free Cash Flow

$16885125120.00

Detailed Analysis
Valuation
JNJ trades at a forward of 20.8x, slightly below its 5-year average of ~21x and near the sector median. The ratio of 4.40 reflects near-term earnings pressure from Stelara biosimilar erosion, but long-term pipeline visibility supports a fair valuation. of 19.2x is in line with large-cap pharma peers. The mean analyst target of $270.59 implies a modest 1.4% upside from $266.73, but the wide range ($190-$305) highlights talc litigation uncertainty. A recent DCF analysis suggests the stock could be 31% undervalued, with an intrinsic value of ~$388. After the Ottava approval, MedTech growth narrative improves, potentially supporting multiple expansion. For a high-quality defensive compounder, current multiples offer reasonable value for long-term investors.
Balance Sheet
Strong balance sheet with a debt-to-equity ratio of 57.7%, manageable net debt of $28.3B, and robust cash generation from operations of $27.6B. The AAA credit rating ensures low-cost capital access. Free cash flow yield of 2.63% is adequate for the sector, supporting dividends and strategic investments.
Growth
Revenue growth of 6.6% YoY in Q2, driven by oncology (DARZALEX, CARVYKTI) and immunology (Tremfya up 72.5%). MedTech grew 4.5%, with strength in Vision, Orthopedics, and Surgery. Adjusted grew 4.7% in Q2. Guidance for FY2026 raised to $11.68 midpoint. Long-term growth is supported by pipeline including ICOTYDE, nipocalimab, and the Ottava launch. The company expects to surpass $100B in revenue in 2026.

Business Quality

Gross margin of 68.1%, operating margin of 29.2%, and margin of 35.6% reflect strong pricing power and operational efficiency. of 25.7% demonstrates capital efficiency. High switching costs, regulatory barriers, and broad diversification across pharma and MedTech support durable competitive advantages.

Capital Allocation

Management prioritizes dividend growth (64 years, $5.40 annual dividend, 60.8% payout ratio) and strategic bolt-on M&A. Share count has remained stable. The dividend yield of 2.02% is sustainable. Recent capital allocation has been shareholder-friendly, with debt reduction and moderate buybacks implied by stable share count.

Estimate Revisions

estimates for FY2026 have been revised up from $11.57 to $11.68 over the past 30 days, and FY2027 from $12.73 to $12.83. Upward revisions outnumber downgrades in the last 7 days (2 up, 0 down). Recent analyst actions include price target raises from Raymond James, Wells Fargo, and Morgan Stanley. Revision momentum is clearly positive.

Revenue Growth

6.6%

Live Feed & Sentiment

Insider Activity

  • DECKER ROBERT J

    Officer

    5,635

    $564k

  • BROADHURST VANESSA

    Officer

    9,809

    —

  • WOODS EUGENE A

    Director

    100

    $15k

  • DECKER ROBERT J

    Officer

    5,635

    $930k

News Catalysts

Jul 28, 2026

Stocks to Watch: SK Hynix, Mercedes-Benz, Coca-Cola, J&J

↘️ Samsung (KR:005930), SK Hynix (KR:000660, SKHY): Shares in both chipmakers dropped more than 13% as part of a broader selloff amid mounting doubts over the AI boom. Over in the U.S., Micron Technology (MU), Intel (INTC) and other chip stocks are also under pressure.

Jul 28, 2026

Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress

Johnson & Johnson stock has delivered a 77.7% total return over the past five years, yet the latest valuation work suggests the current share price may still sit below an intrinsic value estimate based on a Discounted Cash Flow (DCF) model. At the same time, the broader checks paint a less generous picture, so investors are weighing a strong track record against a low overall value score. Over five years, Johnson & Johnson has returned 77.7%, which keeps the stock firmly in focus for...

Jul 28, 2026

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.

Jul 28, 2026

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.